Moreover, SLE patients’ abundant CD19+FSChi polyclonally activated B cells (iBreg cells) have a considerably decreased capacity to inhibit Th cell responses when compared to the same B cell subset in healthy people (194). This evidence concerns the gene CD19 and systemic lupus erythematosus.